CervoMed Inc. Files 8-K on Financials

TL;DR

CervoMed filed an 8-K on May 15th detailing financial condition and results.

AI Summary

CervoMed Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, but does not provide specific financial figures or operational details within the provided text.

Why It Matters

This 8-K filing indicates CervoMed Inc. is providing updates on its financial condition and operational results to the SEC, which is important for investors to monitor the company's performance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial information and does not contain any immediate negative news or significant changes.

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• May 15, 2024 (date) — Date of Report
• 001-37942 (company) — Commission File Number
• 30-0645032 (company) — I.R.S. Employer Identification No.
• 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (company) — Principal executive offices address
• Diffusion Pharmaceuticals Inc. (company) — Former company name
• RestorGenex Corp (company) — Former company name
• Stratus Media Group, Inc (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20240515_8k.htm (8-K) — 29KB
• ex_675383.htm (EX-99.1) — 18KB
• crvo.jpg (GRAPHIC) — 5KB
• 0001437749-24-017132.txt ( ) — 189KB
• crvo-20240515.xsd (EX-101.SCH) — 3KB
• crvo-20240515_def.xml (EX-101.DEF) — 11KB
• crvo-20240515_lab.xml (EX-101.LAB) — 15KB
• crvo-20240515_pre.xml (EX-101.PRE) — 11KB
• crvo20240515_8k_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition Earnings Press Release On May 15, 2024, CervoMed Inc. (the "Company," "we" or "us") issued a press release announcing financial results as of and for the quarter ended March 31, 2024. A copy of that press release is attached hereto as Exhibit99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued May 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 15, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR